Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-08-02
2005-08-02
Carlson, Karen Cochrane (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S308000, C530S322000, C530S402000, C530S412000
Reexamination Certificate
active
06924264
ABSTRACT:
Novel modified exendins and exendin agonist analogs having an exendin or exendin agonist analog linked to one or more polyethylene glycol polymers, for example, and related formulations and dosages and methods of administration thereof are provided. These modified exendins and exendin agonist analogs, compositions and methods are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying or inhibiting food intake.
REFERENCES:
patent: 4766106 (1988-08-01), Katre
patent: 5122614 (1992-06-01), Zalipsky
patent: 5264372 (1993-11-01), Beaumont et al.
patent: 5424286 (1995-06-01), Eng
patent: 5686511 (1997-11-01), Bobo
patent: 6051557 (2000-04-01), Drucker
patent: 6528486 (2003-03-01), Larsen et al.
patent: 0 619 322 (1994-10-01), None
patent: WO 95/07098 (1995-03-01), None
patent: WO 98/05351 (1998-02-01), None
patent: WO 98/08871 (1998-03-01), None
patent: WO9830231 (1998-07-01), None
patent: WO 99/07404 (1999-02-01), None
patent: WO9907404 (1999-02-01), None
patent: WO 99/25727 (1999-05-01), None
patent: WO 99/25728 (1999-05-01), None
patent: WO 99/43708 (1999-09-01), None
Saifer, M. G. P. et al. (2004) “Improved Conjugation of Cytokines Using High Molecular Weight Poly (ethylene glycol): PEG-GM-CSF as a Prototype”, pp. 1-4.
Montrose-Rafizadeh et al. (1997) High potency antagonists of the pancreatic glucagon-like peptide-1 receptor. J. Biol. Chem. vol. 272, pp. 21201-21206.
Broca, C. et al. (1999) -Hydroxyisoleucine: experimental evidence of its insulinotropic and antidiabetic properties. Am. J. Physiol. vol. 277, pp. 617-623.
Raufman, J.-P. et al. (1991) Exendin-3, a novel peptide from Heloderma horridum venom, interacts with vasoactive intestinal peptide receptors and a newly described receptor on dispersed acini from guinea pig pancreas. J Biol .Chem.vol. 266, pp. 2897-2890.
Units, symbols and abbreviation (attachment 1).
Byrne, M.M., et al, “Lessons from human studies with glucagon-like peptide-1: Potential of the gut hormone for clinical use,” in: Insulinotropic Gut Hormone Glucagon-Like Peptide 1, Fehmann, HC editor, Basel, Switzerland: Karger, pp 219-233 (1997).
Chen, Y.E., et al, “Tissue-specific Expression of Unique mRNAs That Encode Proglucagon-derived Peptides or Exendin 4 in the Lizard,”Journal of Biological Chemistry272(7):4108-4115 (1997.
Creutzfeldt, W.O.C., et al, “Glucagonostatic Actions and Reduction of Fasting Hyperglycemia by Exogenous Glucagon-Like Peptide 1(7-36) Amide in Type I Diabetic Patients,” Diabetes Care 19(6) :580-586 (1996).
D'Alessio et al. “Elimination of the Action of glucagon-like Peptide 1 Causes an Impairment of glucose tolerance after Nutrient Ingestion by Healthy Baboons,”J. Clin. Invest., 97:133-38 (1997).
Delgado, C., et al., “The Uses and Properties of PEG-Linked Proteins,”Critical Reviews in Therapeutic Drug CarrierSystems 9(3,4):249-304 (1992.
Egan, J.M., et al, “Glucagon-Like Peptide-1 Restores Acute Phase Insulin Release to Aged Rats,”Diabetologia40(Supp 1):A130 (1997).
Eissele et al. “Rat Gastric somatostatin and Gastrin Release: Interactions of Exendin-4 and Truncated Glucagon-Like Peptide-1 (GLP-1) Amide,”Life Sci., 55:629-34 (1994).
Eng, J., “Prolonged Effect of Exendin-4 on Hyperglycemia of db/db mice,” Diabetes 45(Supp 2):152A (abstract 554) (1996).
Eng et al. “Purification and Structure of Exendin-3, a New Pancreatic Secretagogue Isolated fromHeloderma horridumVenom,”J. Biol. Chem., 265:20259-62 (1990).
Eng et al. “Isolation and Characterization of Exendin-4, an Exendin-3 Analogue, fromHeloderma suspectumVenom”, J.Biol. Chem., 267:7402-05 (1992).
Francis, G.E., et al, “PEGylation of cytokines and other therapeutic proteins and peptides: the importance of biological optimisation of coupling techniques,” International Journal of Hematology 68:1-18 (1998).
Goke, et al. “Exendin-4 Is a High Potency Agonist and Truncated Exendin-(9-39)-amide an Antagonist at the Glucagon-like Peptide 1-(7-36)-amide Receptor of Insulin-secreting -Cells”,J. Biol. Chem., 268:19650-55 (1993).
Gombotz, W.R., et al, “Biodegradable Polymers for Protein and Peptide Drug Deliver,”Bioconjugate Chemistry6:332-351 (1995).
Halaas, J.L., et al, “Weight-Reducing Effects of the Plasma Protein Encoded by the obese Gene,”Science269:543-546 (1995).
Hudecz, F., et al, “Synthesis, Conformation, Biodistribution, and in Vitro Cytotoxicity of Daunomycin-Branched Polypeptide Conjugates,”Bioconjugate Chemistry3:49-57 (1992).
Malhotra et al. “Exendin-4, a new peptide fromHeloderma suspectumvenom, potentiates cholecystokinin-induced amylase release from rat pancreatic acini”,Regulatory Peptides, 41:149-56 (1992).
Meurer, J.A., et al, “Properties of native and in vitro glycosylated forms of the glucagon-like peptide-1 receptor antagonist exendin (9-39),”Metabolism Clinical and Experimental 48(6):716-724 (1999).
O'Halloran et al. “Glucagon-like peptide-1 (7-36)-NH2: a physiological inhibitor of gastric acid secretion in man,”J Endocrinol126 (1): 169-73 (1990).
Ørskov et al. “Biological Effects and Metabolic Rates of Glucagonlike Peptide-1 7-36 Amide and glucagonlike Peptide-1 7-37 in Healthy Subjects Are Indistinguishable”,Diabetes, 42:658-61 (1993).
Pelleymounter, M.A., et al, “Effects of the obese Gene Product on Body Weight Regulation in ob/ob Mice,”Science269:540-543 (1995).
Pratesi, G., et al, “Poly-L-aspartic acid as a carrier for doxorubicin: a comparative in vivo study of free and polymer-bound drug,”British Journal of Cancer52:841-848 (1985).
Raufman et al. “Truncated Glucagon-like Peptide-1 Interacts with Exendin Receptors in Dispersed Acini from Guinea Pig Pancreas”,J. Biol. Chem. 267:21432-37 (1992).
Schepp et al. “Exendin-4 and exendin-(9-39)NH2: agonist and antagonist, respectively, at the rat parietal cell receptor for glucagon-like peptide-1-(7-36)NH2,”Eur. J. Pharm. 269:183-91 (1994).
Schjoldager et al. “GLP-1 (Glucagon-like Peptide 1) and Truncated GLP-1, Fragments of Human Proglucagon, Inhibit Gastric Acid Secretion in Humans,”Dig Dis Sci34 (5): 703-8 (1989).
Singh et al. “Use of125I-[Y39] exendin-4 to characterize exendin receptors on dispersed pancreatic acini and gastric chief cells from guinea pig,”Regul. Pept. 53:47-59 (1994).
Thorens, “Expression cloning of the pancreatic cell receptor for the gluco-incretin hormone glucagon-like peptide 1,”Proc. Natl. Acad. Sci. USA 89:8641-45 (1992).
Tsukada, Y., et al, “An Anti-α-Fetoprotein Antibody-Daunorubicin Conjugate With a Novel Poly-L-flutamic Acid Derivative as Intermediate Drug Carrier,”JNCI73:721-729 (1984).
Turton, M.D., et al, “A role for glucagon-like peptide-1 in the central regulation of feeding,”Nature379 (6560):69-72 (1996).
Veale, P.R., et al, “The presence of islet amyloid polypeptide/calcitonin gen-related peptide/salmon calcitonin binding sites in the rat nucleus accumbens,”European Journal of Pharmacology262:133-141 (1994).
Wettergren et al. “Truncated GLP-1 (Proglucagon 78-107-Amide) Inhibits Gastric and Pancreatic Functions in Man,” Dig Dis Sci 38 (4): 665-73 (1993).
Willms, B., et al, “Gastric Emptying, Glucose Responses, and Insulin Secretion after a Liquid Test Meal: Effects of Exogenous Glucagon-Like Peptide-1 (GLP-1)-(7-36) Amide in Type 2 (Noninsulin-Dependent) Diabetic Patients,”Journal of Clinical Endocrinology and Metabolism 81(1):327-332 (1996).
Zalipsky, S., “Functionalized Poly (ethylene glycol) for Preparation of Biologically Relevant Conjugates,” Bioconjugate Chem 6:150-165 (1995).
Prickett Kathryn S.
Young Andrew A.
Amylin Pharmaceuticals Inc.
Arnold & Porter LLP
Carlson Karen Cochrane
Liu Samuel Wei
LandOfFree
Modified exendins and exendin agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified exendins and exendin agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified exendins and exendin agonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3454954